On August 31, 2026, German neurotechnology company CorTec announced that the U.S. Food and Drug Administration granted its Brain InterchangeTM system a second Breakthrough Device Designation1,2.
The new designation concerns assisting people with non-progressive quadriplegia, using decoded cortical activity to control a computer cursor. CorTec’s earlier April 2026 designation concerned therapeutic cortical stimulation for post-stroke motor rehabilitation. This previous approval was accompanied by a clinical study performed at the University of Washington3. However, this recent designation lacks any corresponding study results.
What does this Designation entail?
This designation means that CorTec’s brain-computer interface (BCI) system called Brain InterchangeTM will receive special treatment from the FDA. It will allow for the company to streamline the development of their device in terms of getting it to a commercially viable state. It also indicates that the FDA believes the device is safe enough to test on patients suffering from life-long illnesses with no treatments4.
Importantly, it does not establish the safety or effectiveness, eliminate the need for clinical evidence, or guarantee eventual authorization of the BCI for commercial purposes. This development should only be taken as a regulatory-development milestone and does not mean FDA marketing authorization. However, this approval does allow for the expedited testing of CorTec’s BCI for those suffering from non-progressive quadriplegia.
Significance for the Development of BCIs and Patient Well-being
Though all implantable BCIs require surgical implantation, which puts strain on the patients, Brain InterchangeTM implants are relatively superficial. They are placed right under the scalp and thus negate any actual need for piercing through brain tissue.
This is also notable development for the BCI field because CorTec’s Brain Interchange system can both record neural activity and deliver electrical stimulation to the brain. This bidirectional capability allows the system to read signals from the brain and provide stimulation in response, creating the potential for closed-loop therapeutic applications. Such closed loop systems mitigate the need of external inputs, making them a safer alternative to other BCI models in regards to storage and access to patient’s neural data.
Limitations of Cortec’s BCI
In their announcement post, CorTec states “A cursor on a screen is a small thing, unless it is the only part of the world you can still move.” Though poetic and a very real improvement for many with quadriplegia, this promise in comparison to other BCI devices going through clinical trials, can be said to be underwhelming, but unlike other devices such promise are grounded in studies. It under sells the potential of BCIs to completely restore mobility in the lives of those who have lost it.
Another caveat of the Brain Exchange system, is that it is limited to the brain’s outer layer, or the cortex. The cortex is a major brain center for higher-level cognition, including complex, planned motor movements. But certain motor functions will also require input from deeper brain tissue, such as the thalamus, basal ganglia and brain stem — structures that are vital for motor control. Without access to these underlying structures the therapeutic value of Brain Exchange may be limited.
Main Takeaways
- FDA approval will allow CorTec to expedite its BCI development.
- CorTec’s closed bidirectional Brain Exchange system is unique to the other leading BCI lines.
- It is less invasive than other leading BCI lines like Neuralink and Paradromics, however this will also limit its therapeutic value.
References
- https://cortec-neuro.com/news/cortec-receives-second-fda-breakthrough-device-designation-for-brain-interchange
- https://www.eqs-news.com/news/corporate/cortec-receives-second-fda-breakthrough-device-designation-for-brain-interchange/d6bcc0e9-2a99-4e27-8c0d-1224a3abcf36_en
- https://clinicaltrials.gov/study/NCT06506279
- https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program#s1
Leave a Reply